Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in two upcoming investor conferences: the 9th Annual Evercore Healthcare Conference in Miami, FL, and the Piper Sandler 38th Annual Healthcare Conference in New York, NY. The company will hold fireside chats and one-on-one investor meetings at these events in late November and early December 2026. Webcasts of the fireside chats will be accessible on the investor page of the Harmony Biosciences website.
Two conference talks will be webcast by Harmony Biosciences, with events in Miami and New York.
Harmony Biosciences Holdings (HRMY) management will participate in two upcoming investor conferences, featuring fireside chats that will be webcast. The first event is the 9th Annual Evercore Healthcare Conference in Miami on November 30, 2026, followed by the Piper Sandler 38th Annual Healthcare Conference in New York on December 3, 2026. These participations highlight the company's engagement with the investment community.
There May Be Reason For Hope In Harmony Biosciences Holdings' (NASDAQ:HRMY) Disappointing Earnings
Harmony Biosciences Holdings (NASDAQ:HRMY) recently reported earnings that disappointed shareholders, but an analysis of its accrual ratio suggests underlying strength. The company's accrual ratio of -0.24 indicates that its statutory earnings were significantly less than its free cash flow, with US$272m in FCF against US$178.6m in reported profit. This strong conversion of profit to free cash flow, coupled with a 22% annual EPS increase over the last three years, suggests that Harmony Biosciences' true earnings potential might be better than its reported profit figures imply.
Harmony Biosciences Profit Falls Despite 12% Sales Growth
Harmony Biosciences Holdings Inc. reported a decline in third-quarter profit to $48.2 million, or 81 cents per diluted share, despite a 12% increase in sales of its narcolepsy treatment WAKIX, which generated $268.9 million. This profit fall was attributed to higher licensing costs and increased research and development spending. The company is reaffirming its full-year WAKIX revenue forecast and investing in experimental treatments like BP-205, while also defending its intellectual property.
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
Harmony Biosciences (HRMY) reported Q3 2026 earnings of 81 cents per share, missing the Zacks Consensus Estimate of $1.00 due to higher research and development expenses and milestone charges. Despite the earnings miss, quarterly revenues increased 12% year over year to $269 million, driven by strong demand for its lead drug, Wakix. The company reaffirmed its full-year 2026 Wakix net revenue guidance of $1 billion to $1.04 billion and is advancing several pipeline candidates.
Earnings call transcript: Harmony Biosciences misses Q3 2026 profit view
Harmony Biosciences reported Q3 2026 earnings per share of $0.81, missing the $1.11 forecast, and revenue of $268.9 million, slightly below the $274.55 million expectation. Despite strong demand for its narcolepsy drug WAKIX, which saw 400 net patient additions and revenue growth, profitability was impacted by higher royalties and a $25 million milestone charge. The company reiterated its full-year WAKIX revenue guidance of $1.0 billion to $1.04 billion and discussed advancements in its pipeline, including promising early data for its orexin-2 agonist, BP-205.
Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming
Harmony Biosciences reported a third-quarter miss primarily due to increased royalty costs and decelerating growth of its WAKIX franchise, rather than a drop in demand. While patient additions remained steady, higher costs of products sold, attributed to new royalties, squeezed gross and operating margins. The company faces upcoming competitive pressure and crucial patent rulings in February 2027, adding execution uncertainty amidst a CEO transition.
Harmony Biosciences Q3 Earnings Call Highlights
Harmony Biosciences reported strong Q3 net revenue of $269 million, driven by continued demand for its narcolepsy treatment, WAKIX, and reiterated its full-year WAKIX revenue guidance of over $1 billion. The company also presented preliminary data for its pipeline candidate BP-205 and discussed ongoing patent defense efforts and an upcoming CEO transition. Harmony ended the quarter with over $1 billion in cash and is actively pursuing business development opportunities for future growth.
Harmony Biosciences Plans CEO Transition for 2027
Harmony Biosciences has announced a leadership transition, with Peter Anastasiou set to become president, CEO, and board member on January 1, 2027. Current CEO Jeffrey M. Dayno, MD, will retire at the end of 2026 and serve as a non-executive advisor for the following year. The company reaffirmed its 2026 net revenue guidance for its narcolepsy treatment, WAKIX, and expects to release data from a multiple ascending dose study in Q4 2026.
Harmony Biosciences Hldgs Q3 2026 Earnings Call Transcript
Harmony Biosciences reported strong Q3 2026 financial results with WAKIX net revenue of $269 million, on track to exceed $1 billion for the year. The company announced a CEO transition, with Peter Anastasiou taking over in 2027, and highlighted promising preliminary Phase 1 data for its orexin 2 receptor agonist, BP205. Harmony is actively defending its WAKIX intellectual property through ongoing litigation and pursuing strategic acquisitions to expand its CNS market leadership.
Q3 sales rose to $268.9M, but profit fell at Harmony Biosciences (HRMY).
Harmony Biosciences Holdings, Inc. (HRMY) reported an increase in third-quarter net product revenue to $268.9 million, up from $239.5 million a year prior, but saw its net income decline to $48.2 million from $50.9 million. For the first nine months of 2026, revenue increased to $745.6 million, and net income rose to $156.1 million. The company's cash and investments totaled over $1 billion, which management believes will cover liquidity needs and fund investments for at least the next twelve months.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
Harmony Biosciences Holdings, Inc. (HRMY) reported Q3 earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share, and revenues of $268.92 million, also falling short of expectations. The company's stock has underperformed the S&P 500 year-to-date. Investors are now looking to future earnings outlook and management commentary for insights into the stock's potential movement.
Harmony Biosciences reports Q3 revenue of $269M, reaffirms guidance By Investing.com
Harmony Biosciences reported Q3 net revenue of $269 million for its WAKIX product, adding 400 net patients to reach an estimated average of 9,350. The company reaffirmed its full-year revenue guidance of $1.0 billion to $1.04 billion for WAKIX and provided preliminary data for its investigational drug BP-205, which is an orexin-2 receptor agonist. Net income for the quarter was $48.2 million, or $0.81 per diluted share, a decrease from the prior year due to increased milestone charges and royalty payments.
Harmony Biosciences stock faces November 4 earnings catalyst
Harmony Biosciences is set to release its third-quarter 2026 financial results on November 4, providing investors with an update on WAKIX sales and its rare-neurology pipeline. The company has reaffirmed its 2026 WAKIX net revenue guidance and is advancing its investigational orexin-2 receptor agonist, BP-205, with data expected in Q4 2026. Investors will closely watch WAKIX prescription and revenue trends, management's outlook, and pipeline development milestones.
Form 144 HARMONY BIOSCIENCES HOLDINGS For: 2 November By Investing.com
This article announces that Harmony Biosciences Holdings (HRMY) has filed a Form 144 for November 2nd. A Form 144 indicates an intent to sell restricted or control securities. The article provides the title and date, but no further details on the filing.
Harmony Biosciences stock faces earnings test on November 4
Harmony Biosciences (HRMY) is set to release its third-quarter 2026 results before U.S. markets open on November 4, followed by a conference call at 8:30 a.m. Eastern Time. Investors will focus on the company's commercial performance of WAKIX, progress in pitolisant applications, and the advancement of HBS-301 in Phase 3 studies for rare neurological disorders. The earnings call will also offer updates on upcoming clinical milestones for the Plymouth Meeting, Pennsylvania-based pharmaceutical company.
(HRMY) and the Role of Price-Sensitive Allocations
Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) shows strong near-term sentiment with a mid-channel oscillation pattern, presenting an exceptional 51.0:1 risk-reward setup targeting a 15.0% gain. AI models suggest distinct trading strategies for various risk profiles, including long, breakout, and short positions based on multi-timeframe signal analysis. The stock exhibits a positive bias towards the long term.
Harmony Biosciences Sets November 4 Earnings Report
Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) announced it will report its third-quarter 2026 financial results on November 4, before U.S. financial markets open. The pharmaceutical company, focused on rare neurological diseases, will hold a conference call and webcast at 8:30 a.m. Eastern Time for investors to discuss its financial performance and operations.
BlackRock reports a passive stake in Harmony Biosciences (HRMY), with an iShares ETF holding over 5%.
BlackRock, Inc. has reported a 12.6% beneficial ownership stake in Harmony Biosciences Holdings, Inc. (HRMY), amounting to 7,361,888 common shares as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 7,269,051 shares and sole dispositive power over all beneficially owned shares. Notably, the iShares Core S&P Small-Cap ETF, managed by BlackRock, holds an interest exceeding 5% of Harmony Biosciences' outstanding common stock.
Harmony Biosciences Holdings Inc. Company & People | HRMY
Harmony Biosciences Holdings Inc. (HRMY) is a commercial-stage pharmaceutical company focused on neurological disorders, with its key product WAKIX. The article provides detailed company information including market data, analyst ratings, key executives, financial performance metrics like profitability, efficiency, and capitalization ratios. It highlights the company's financial health, executive team, and a summary of its business operations.
Harmony Biosciences Holdings Inc. Research & Ratings | HRMY
This article provides research and ratings for Harmony Biosciences Holdings Inc. (HRMY), a commercial-stage pharmaceutical company specializing in treatments for neurological disorders. It includes analyst ratings with an average price target of $48.25 and an average "Hold" score, along with detailed financial data, quarterly actuals, and yearly estimates for earnings. The company's product, WAKIX, is highlighted for its novel mechanism in treating neurological conditions.
HRMY | Harmony Biosciences Holdings Inc. Stock Overview (Mexico)
This article provides an overview of Harmony Biosciences Holdings Inc. (HRMY) stock in the Mexico market, including current stock performance, key financial data, and analyst ratings. It also lists major holders and key executives, offering a comprehensive snapshot of the company's market presence and structure.
Harmony Biosciences Holdings, Inc. Estimates – NASDAQ:HRMY
This page on TradingView provides financial actuals and analyst estimates for Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). Users can explore reported financial data and compare it with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also offers tools to visualize financial trends over time for both annual and quarterly periods.
Harmony Biosciences Holdings, I (HRMY) Stock forecasts
Argus has raised its target price for Harmony Biosciences Holdings Inc (HRMY) to $43.00, citing the company's focus on developing and commercializing therapies for rare neurological diseases. Harmony Biosciences is a commercial-stage pharmaceutical company dedicated to addressing unmet medical needs in this patient population.
Mizuhoon Harmony Biosciences (HRMY): 'we recommend being opportunistic on yesterday's share weakness'
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and a $51.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The analyst recommends being opportunistic on the stock following its recent weakness. The full article content is premium-only and requires a subscription to StreetInsider.com Premium.
Harmony Biosciences Shares Fall 7% as Wakix Patent Arguments Unfold
Harmony Biosciences Holdings, Inc. (HRMY) experienced a 7% drop in its share price on October 22 as closing arguments commenced in a patent dispute concerning its drug, Wakix. The litigation, an ANDA patent case, is ongoing in Wilmington, Delaware, between Harmony and AET Pharma.
Centene, Harmony Biosciences lead list of undervalued healthcare stocks
As the third-quarter 2026 earnings season progresses, a quantitative screen by Seeking Alpha has identified seven undervalued healthcare stocks. Centene Corporation and Harmony Biosciences Holdings lead this list with A+ valuation grades. Other companies with A grades include Cigna Group, CVS Health, DaVita, Molina Healthcare, and Pfizer, based on their pricing relative to fundamentals.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences Holdings, Inc. announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these results. Details for participating in the call and accessing the webcast replay are provided.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences will release its third-quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call and webcast on the same day to discuss the results and provide a business update. Investors and interested parties can access the webcast or dial into the conference call.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences Holdings, Inc. announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, before the U.S. financial markets open. The company will also host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these results. Interested parties can access the webcast on Harmony Biosciences' investor relations website.
Harmony Biosciences to report Q3FY27 results on November 4
Harmony Biosciences Holdings will release its third-quarter 2026 financial results on November 4, 2026, before U.S. financial markets open. The company, which specializes in therapies for rare neurological diseases, will host a conference call and webcast at 8:30 am ET to discuss the results. This announcement is a key update for stakeholders interested in the company's progress with innovative treatments.
A drugmaker developing treatments for rare brain disorders will discuss results at 8:30 a.m. ET Nov. 4.
Harmony Biosciences Holdings (HRMY) announced it will report its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open. The company will also host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these results. This announcement provides details for investors and stakeholders to access the earnings information and subsequent discussion.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these results. Details for participating in the call and accessing the webcast are provided.
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these results. Interested parties can access the webcast on the investor page of Harmony Biosciences' website.
Weekly Recap: 2026 WAKIX revenue guidance and CEO Dayno retirement
Harmony Biosciences (HRMY) reaffirmed its 2026 WAKIX revenue guidance at $1.0–$1.04 billion and expects Q4 2026 data for BP-205. This news comes amidst the retirement of CEO Dayno and the succession of the COO, which caused a decline in share price despite ongoing efforts to advance its pitolisant franchise and CNS pipeline.
Harmony Names New CEO, Reaffirms $1 Billion Revenue Outlook
Harmony Biosciences Holdings Inc. has appointed Peter Anastasiou as its new CEO, effective January 1, 2027, succeeding Jeffrey M. Dayno. The company reaffirmed its 2026 revenue guidance of $1 billion to $1.04 billion for its narcolepsy treatment WAKIX and plans to expand its central nervous system drug portfolio and advance clinical development programs under Anastasiou's leadership.
HRMY Reiterated by Needham -- Price Target Maintained at $50.00
Needham has reiterated its "Buy" rating for Harmony Biosciences (HRMY), maintaining a $50.00 price target. The company is considered 20.5% undervalued with a strong GF Score™ of 95/100, driven by excellent growth and valuation metrics. Despite mixed guru activity and insider selling, HRMY is seen as a compelling opportunity for investors in the healthcare sector, particularly in rare neurological diseases.
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Harmony Biosciences Holdings, Inc. (HRMY) has seen a 27.6% surge in its stock over the past six months, driven by strong demand for its lead drug Wakix and promising pipeline developments. The company's financial flexibility, strong revenue growth from Wakix, and ongoing pipeline progress with BP-205 and EPX-100 suggest potential for continued growth, despite patent litigation and market competition. Analysts recommend HRMY as a "Strong Buy" due to its favorable long-term prospects.
Harmony Biosciences names Anastasiou CEO: Ladenburg targets Harmony Biosciences stock at USD 55.00
Harmony Biosciences has appointed Peter Anastasiou as its new CEO, effective January 1, 2027, with Jeffrey M. Dayno retiring on December 31, 2026. The company reiterated its full-year 2026 WAKIX net revenue guidance of USD 1.00 billion to USD 1.04 billion, following a strong second quarter with USD 261.28 million in revenue. The leadership transition coincides with ongoing Phase 3 trials for HBS-301 and continued focus on its central nervous system pipeline, with a market capitalization of USD 2.2 billion as of October 15, 2026.
Ladenburg Thalmann Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy
Ladenburg Thalmann analyst Caroline Palomeque has initiated coverage on Harmony Biosciences Holdings Inc. (HRMY) with a "Buy" rating. The article, published on October 15, 2026, indicates that this new coverage was announced at 7:17 AM EDT. Further details are exclusively available to premium subscribers.
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Disc Medicine (IRON)
Two healthcare companies, Harmony Biosciences Holdings (HRMY) and Disc Medicine (IRON), have received bullish sentiments from analysts. H.C. Wainwright reiterated Buy ratings for both companies, setting price targets of $55.00 for Harmony Biosciences and $120.00 for Disc Medicine. Harmony Biosciences holds a Moderate Buy consensus with a $44.00 average price target, while Disc Medicine has a Strong Buy consensus with a $102.22 price target.
H.C. Wainwright reiterates Harmony Biosciences stock rating on leadership transition
H.C. Wainwright maintained a Buy rating and $55 price target for Harmony Biosciences Holdings Inc. following the announcement of a leadership transition, with Peter Anastasiou set to succeed Jeffrey Dayno as CEO in 2027. The company reaffirmed its 2026 WAKIX net revenue guidance of $1.00 billion to $1.04 billion, aligning with analyst estimates. Harmony Biosciences has shown a strong 45% return over the past year and expects to release BP-205 multiple ascending dose data in Q4 2026.
Harmony CEO Jeffrey M. Dayno to Retire; Peter Anastasiou Named Successor
Harmony Biosciences announced that CEO Jeffrey M. Dayno will retire effective December 31, 2026, and step down from the board. Current Chief Operating Officer Peter Anastasiou will succeed him as President and CEO and become a Class I director starting January 1, 2027. Dayno will serve as a non-executive advisor through 2027 as part of a leadership succession plan.
H.C. Wainwright reiterates Harmony Biosciences stock rating on leadership transition
H.C. Wainwright has reiterated a Buy rating and $55 price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) following the announcement of a leadership transition, with Peter Anastasiou succeeding Jeffrey Dayno as CEO in January 2027. The company reaffirmed its 2026 WAKIX net revenue guidance of $1.00 billion to $1.04 billion, aligning with analyst estimates. Harmony Biosciences has shown strong performance, with a 45% return over the past year and recent positive earnings, and its stock appears undervalued according to InvestingPro analysis.
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (HRMY). The analyst also maintained a price target of $55.00 for the company's stock. This article is a premium-only piece on StreetInsider.com.
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Harmony Biosciences announced a planned CEO transition, with Peter Anastasiou appointed as the new President, CEO, and board member, effective January 1, 2027. He will succeed Jeffrey M. Dayno, M.D., who will retire at the end of 2026 after a nine-year tenure. The company reiterated its full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion and confirmed it is on track to report data from the BP-205 MAD study in Q4 2026.
Harmony Biosciences names Peter Anastasiou as next CEO
Harmony Biosciences Holdings, Inc. announced Peter Anastasiou will become President and Chief Executive Officer effective January 1, 2027. He will succeed Jeffrey M. Dayno, who retires on December 31, 2026. The company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and remains focused on growing its pitolisant franchise and advancing its CNS pipeline.
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Harmony Biosciences announced that Peter Anastasiou will succeed Jeffrey M. Dayno, M.D., as President and CEO, effective January 1, 2027. Dr. Dayno will retire at the end of 2026 but will serve as a non-executive advisor throughout 2027 to support the transition and growth objectives. The company reiterated its full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion and remains on track to report data from the BP-205 MAD study in Q4 2026.
Harmony Biosciences names Peter Anastasiou as next CEO By Investing.com
Harmony Biosciences Holdings, Inc. announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Anastasiou currently serves as Senior Executive Vice President and Chief Operating Officer and previously held positions at Capsida Biotherapeutics and Lundbeck. The company reaffirmed its full-year 2026 WAKIX net revenue guidance and expects to report data from its BP-205 study in Q4 2026.
Harmony Biosciences Names Peter Anastasiou CEO Effective January 1, 2027; Reaffirms 2026 WAKIX Guidance
Harmony Biosciences announced that Peter Anastasiou will become President and CEO on January 1, 2027, succeeding Jeffrey M. Dayno, who retires after a nine-year tenure. Dayno will remain as a non-executive advisor during the transition. The company reaffirmed its full-year 2026 net revenue guidance for WAKIX at $1.0 billion to $1.04 billion and expects to report BP-205 study data in Q4 2026, focusing on expanding its CNS pipeline and maintaining WAKIX exclusivity.